Equibles does not estimate personal net worth.
Get an email with a short summary when Lexicon Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get LXRX alertsMike Exton, Ph.D. is recorded as CEO at Lexicon Pharmaceuticals, Inc. (LXRX). Mike Exton, Ph.D. has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Lexicon Pharmaceuticals, Inc. on September 14, 2026. Lexicon Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lexicon Pharmaceuticals, Inc. includes Michael Exton, Ph.D. (CEO and Board Member), Michael S. Exton (CEO and Board Member), Raymond Debbane (Chairman) and 7 others.
“And meeting season is well underway here, and we're really happy to be here with HC Wainwright this week and appreciate the invitation. Actually, this meeting comes at a very important juncture for Lexicon in our transformation towards a focused cardiometabolic company.”
“Look, I want to begin by focusing on our most recent and major accomplishment, the completion of enrolment in Sonata HCM, our phase three study of sodagoplozin in hypertrophic cardiomyopathy or HCM.”
“Look, we've come here really at a very important time for Lexicon's history.”
“We're really excited to give you updates on the quarter and all of the great work going on at Lexicon. When we entered 2025, if you recall, we were still in the early days of strategic pivot to being an R&D focused company and now in the second half of the year I can say that this transformation has truly taken shape.”
Biotechnology · Healthcare
CEO
